Evidence map›Paper›PMID 28218757›Full record

ArticleBone marrow transplantation2017

Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience.

P O'Hare, G Lucchini, M Cummins, P Veys, M Potter, S Lawson, A Vora, R Wynn, A Peniket, K Kirkland and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Novel juxtamembraneFrontiers in oncology · 2026
    Article
  3. Review
  4. Article
  5. Haploidentical HSCT in the Treatment of Pediatric Hematological Disorders.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

P O'HareBone Marrow Transplantation Department, Great Ormond Street Hospital, London, UK.
G LucchiniBone Marrow Transplantation Department, Great Ormond Street Hospital, London, UK.
M CumminsPediatric Bone Marrow Transplant Department, Bristol Royal Children's Hospital, Bristol, UK.
P VeysBone Marrow Transplantation Department, Great Ormond Street Hospital, London, UK.
M PotterHemato-Oncology Unit, Royal Marsden Hospital, London, UK.
S LawsonDepartment of Haematology, Birmingham Children's Hospital, Birmingham, UK.
A VoraDepartment of Paediatric Haematology, Sheffield Children's Hospital, Sheffield, UK.
R WynnRoyal Manchester Children's Hospital, Manchester, UK.
A PeniketHematology Department, Oxford University Hospital, Oxford, UK.
K KirklandBritish Society for Blood and Marrow Transplantation Registry, Guy's Hospital, London, UK.
R PearceBritish Society for Blood and Marrow Transplantation Registry, Guy's Hospital, London, UK.
J PerryBritish Society for Blood and Marrow Transplantation Registry, Guy's Hospital, London, UK.
P J AmroliaBone Marrow Transplantation Department, Great Ormond Street Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report outcomes for 44 children who underwent stem cell transplantation (SCT) for refractory AML in the UK between 2000 and 2012. Median age at SCT was 11.5 years. Twenty-three patients had primary refractory and 21 relapsed refractory AML. Refractory disease was confirmed by cytogenetics/molecular genetics in 24 cases. Median follow-up of the whole cohort is 6.8 years (2.1-14.9 years). Thirty patients (68%) achieved a CR following SCT. Transplant-related mortality at 1 year was 18%. Acute GVHD incidence was 52% (grade ⩾III 19%), chronic 7%. Relapse was the major cause of treatment failure and occurred in 32% of patients at a median of 61 days post SCT. Five-year overall survival and leukemia-free survival (LFS) were 43% (95% CI 31-61%). All patients with favorable cytogenetics (n=6) are alive in CR. Outcomes in patients with primary refractory disease were equivalent to those with relapsed refractory AML. Blast percentage ⩽30% in the BM pre-SCT, myeloablative conditioning and acute GVHD proved to be favorable prognostic features. We could stratify patients according to age ⩾10 years and >30% blasts in BM pre-SCT. Patients with none/one of these risk factors were highly salvageable (5 years LFS 53%) whereas those with both factors had a very poor prognosis (5 years LFS 10%). This may facilitate decision making on whether it is appropriate to consider transplant in such patients.

Indexed as

Hematopoietic Stem Cell TransplantationAcute DiseaseAdolescentAllograftsChildChild, PreschoolChromosome AberrationsDisease-Free SurvivalFemaleFollow-Up StudiesGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteMaleRecurrenceSurvival Rate

Identifiers

PMID28218757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.